Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CCR2 | P41597 | 3/20 | 0.52 |
| ▸ | CCR1 | P32246 | 2/20 | 0.52 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | BRD1 | O95696 | 1/20 | 0.44 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4697760 | 0.93 | CCR2 (0.56) | PPARGCCR2CCR1SLC22A12CYP3A4 | |
| SCHEMBL4696965 | 0.89 | PPARG (0.54) | PPARGCCR2CCR1SLC22A12CYP3A4 | |
| SCHEMBL4696893 | 0.83 | PPARG (0.58) | PPARGLMNACCR2SLC22A12CYP3A4 | |
| SCHEMBL12584711 | 0.82 | PPARG (0.65) | PPARGLMNASLC22A12CYP3A4KMT2A | |
| SCHEMBL4696073 | 0.81 | PPARG (0.69) | PPARGCYP3A4 | |
| SCHEMBL12584598 | 0.77 | PPARG (0.66) | PPARGSLC22A12CYP3A4 | |
| SCHEMBL5665407 | 0.74 | CCR2 (0.79) | CCR2CCR1MAPTKDM4ECYP3A4 | |
| SCHEMBL1471705 | 0.74 | AXL (0.53) | LMNACCR2CCR1MAPTGAA | |
| SCHEMBL4807828 | 0.74 | PPARG (0.77) | PPARGLMNACYP3A4GAA | |
| SCHEMBL14031307 | 0.73 | CYP19A1 (0.61) | PPARGLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1657244-B1 | 2-thiaquinolizidines as glycosidase and glycosyltransferase inhibitors | UNIV MICHIGAN STATE (US) | 2008-10-15 | — | — | EP | claimed |
| EP-1053227-B1 | PPAR-GAMMA MODULATORS | AMGEN INC (US) | 2008-11-05 | — | — | EP | disclosed |
| US-7439242-B2 | PPARγ modulators | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439242-B2 | PPARγ modulators | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439242-B2 | PPARγ modulators | AMGEN INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-6620827-B2 | Peroxisome proliferator-activated receptors-gamma to control lipid metabolism ane obesity; antidiabetic, -inflammatory and -arthritic agents; non-insulin dependent diabetes; antilipemic and -cholesterol agents | TULARIK INC. | 2003-09-16 | — | — | US | disclosed |
| US-20030088103-A1 | PPARgamma modulators | TULARIK INC. (US) | 2003-05-08 | — | — | US | disclosed |
| US-20010027200-A1 | PPARgamma modulators | TULARIK INC. | 2001-10-04 | — | — | US | disclosed |
| US-6200995-B1 | PYRIDYLOXYBENZENESULFONAMIDE DERIVATIVES; DIABETES, OBESITY | TULARIK INC. | 2001-03-13 | — | — | US | disclosed |
| EP-1053227-A1 | PPAR-GAMMA MODULATORS | TULARIK, INC. (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999038845-A1 | PPAR-GAMMA MODULATORS | TULARIK INC. (US) | 1999-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030088103-A1 | PPARgamma modulators | PPARG, PPARA, PPARD | PPARG 1/4885LMNA 2066/4885CCR2 1544/4885 |
| US-20010027200-A1 | PPARgamma modulators | PPARG, PPARA, PPARD | PPARG 1/4885LMNA 2066/4885CCR2 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.